中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.013 seconds)

    USE OF ASTAXANTHIN FOR REDUCING PROGRESSION OF DAMAGE CAUSED TO HUMAN SKIN
    1.
    发明申请
    USE OF ASTAXANTHIN FOR REDUCING PROGRESSION OF DAMAGE CAUSED TO HUMAN SKIN 审中-公开
    用ASTAXANTHIN减少人体皮肤损伤的进展

    公开(公告)号：WO2018062427A1

    公开(公告)日：2018-04-05

    申请号：PCT/JP2017/035327

    申请日：2017-09-28

    Applicant: ASTAREAL CO., LTD.

    Inventor： TOMINAGA Kumi ,  FUJISHITA Mayuko ,  HONGO Nobuko

    IPC: A61K31/122 ,  A23L33/10 ,  A61K36/05 ,  A61P17/16 ,  A61Q19/00

    CPC classification number: A61P17/16 ,  A23L33/10 ,  A61K8/35 ,  A61K31/122 ,  A61K36/05 ,  A61P17/18 ,  A61Q19/08

    Abstract: The use of at least any one of astaxanthin and an astaxanthin-containing composition for reducing the progression of damage caused to human skin by an external factor, and a method for reducing the progression of damage caused to human skin by an external factor, the method including allowing astaxanthin to be ingested, each according to the present invention, provide a food-and-drink composition, food-and-drink, pharmaceutical composition, and agent to reduce the worsening of the state of damaged human skin.

    Abstract translation: 使用虾青素和含虾青素的组合物中的至少任一种用于减少由外因引起的对人皮肤的损伤的进展，以及减少对人造成的损害的进展的方法 通过外部因素皮肤吸收虾青素的方法，本发明提供一种食品饮料组合物，食品饮料，医药组合物和药剂，以减少虾青素的状态恶化 受损的人体皮肤。

    TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA)
    4.
    发明申请
    TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA) 审中-公开
    用TRIIOTOTHYROACTICACID（TRIAC）和脱氢叶酸酯（DHEA）的组合处理皮肤ATROPHY

    公开(公告)号：WO2016083325A1

    公开(公告)日：2016-06-02

    申请号：PCT/EP2015/077401

    申请日：2015-11-24

    Applicant: FAERGEMANN, Jan ,  JOHANNSSON, Gudmundur ,  OHLSSON, Claes ,  BATCHELLER, Derek Gregory ,  JOHNSSON, Jörgen ,  TÖRNELL, Jan

    Inventor： FAERGEMANN, Jan ,  JOHANNSSON, Gudmundur ,  OHLSSON, Claes ,  BATCHELLER, Derek Gregory ,  JOHNSSON, Jörgen ,  TÖRNELL, Jan

    IPC: A61K31/192 ,  A61K31/5685 ,  A61P17/18 ,  A61P17/16 ,  A61P17/10 ,  A61P17/08 ,  A61P17/06 ,  A61P17/02 ,  A61P17/00

    CPC classification number: A61K31/5685 ,  A61K8/06 ,  A61K8/062 ,  A61K8/365 ,  A61K8/63 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K31/192 ,  A61K45/06 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P17/08 ,  A61P17/10 ,  A61P17/16 ,  A61P17/18 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2300/00

    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit. This study has for the first time shown that a combination of TRIAC and DHEA could effectively stimulate collagen synthesis in skin pretreated with betamethasone valerate demonstrated by an increase in PINP, and that the combination was more effective than TRIAC or DHEA alone. This combination could be used to effectively treat skin atrophy in corticosteroid induced skin atrophy. It could also be used to treat skin atrophy due to other circumstances such as e. g. sun damaged skin and skin atrophy due to high age. Another interesting application would be to combine TRIAC and DHEA with a potent corticosteroid in order to prevent corticosteroid induced skin atrophy. If this combination still is effective in the treatment of eczema and psoriasis and without the risk of skin atrophy this combination will be a major breakthrough for the use of potent topical corticosteroids.

    Abstract translation: 本研究的目的是调查三碘甲基乙酸（TRIAC）和脱氢表雄酮（DHEA）的组合与单独的TRIAC，DHEA或安慰剂组合对皮质类固醇诱导人类胶原合成的影响。 参加了六十岁的40-65岁健康男性志愿者。 用倍他米松戊酸酯霜预处理4个腹部皮肤区域3周。 然后在相同的奶油载体中使用以下替代物之一处理相同的区域：TRIAC，DHEA，TRIAC + DHEA和安慰剂2周。 然后用真空泵将这些区域中的每个区域吸起水泡。 收集每个区域的水泡液，冷冻至分析。 使用市售的免疫测定（Orion Diagnostics）试剂盒进行吸入泡状液中人I型前胶原（PINP）的氨基末端前肽的分析。 这项研究首次表明，TRIAC和DHEA的组合可以有效地刺激皮下预处理的皮肤胶原蛋白合成，通过PINP增加证明戊酸倍他米松，并且该组合比单独的TRIAC或DHEA更有效。 这种组合可用于有效治疗皮质类固醇诱导的皮肤萎缩中的皮肤萎缩。 它也可以用于治疗由于其他情况如e的皮肤萎缩。 G。 太阳损伤皮肤和皮肤萎缩由于年龄高。 另一个有趣的应用是将TRIAC和DHEA与强效皮质类固醇结合，以防止皮质类固醇诱导的皮肤萎缩。 如果这种组合在治疗湿疹和牛皮癣方面仍然有效，并且没有皮肤萎缩的风险，则这种组合将是使用强效局部皮质类固醇的重大突破。

Patent Agency Ranking